Angiogenic Switch in Patients With Colorectal Cancer
NCT02075086
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
Xelox or Xeliri Bevacizumab
Sponsor
Grupo Hospital de Madrid